{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T22:50:27Z","timestamp":1770418227177,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jceh.2020.05.003","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T12:15:58Z","timestamp":1589890558000},"page":"37-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Tenofovir is Superior to Entecavir in Patients with Treatment-na\u00efve Hepatitis B e-Antigen\u2013Positive Chronic Hepatitis B"],"prefix":"10.1016","volume":"11","author":[{"given":"Manas K.","family":"Behera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girish K.","family":"Pati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8451-1558","authenticated-orcid":false,"given":"Jimmy","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debakanta","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lalit K.","family":"Meher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaskant","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanishka","family":"Uthansingh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoj K.","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2020.05.003_bib1","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2020.05.003_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.7869\/tg.2012.23","article-title":"Lower chronic hepatitis B in South Asia despite all odds: bucking the trend of other infectious diseases","volume":"33","author":"Puri","year":"2012","journal-title":"Trop Gastroenterol"},{"key":"10.1016\/j.jceh.2020.05.003_bib3","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJMoa013215","article-title":"Hepatitis B e antigen and the risk of hepatocellular carcinoma","volume":"347","author":"Yang","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2020.05.003_bib4","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2011.06.036","article-title":"Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma","volume":"141","author":"Chen","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2020.05.003_bib5","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.antiviral.2013.08.020","article-title":"Predictors of survival in hepatitis B virus related decompensated cirrhosis on tenofovir therapy: an Indian perspective","volume":"100","author":"Srivastava","year":"2013","journal-title":"Antivir Res"},{"key":"10.1016\/j.jceh.2020.05.003_bib6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2893.2012.01602.x","article-title":"First-line treatment of chronic hepatitis B with entecavir or tenofovir in real-life settings: from clinical trials to clinical practice","volume":"19","author":"Pol","year":"2012","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jceh.2020.05.003_bib7","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/apt.12629","article-title":"Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA","volume":"39","author":"Gao","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2020.05.003_bib8","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.gastro.2012.05.037","article-title":"Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-na\u00efve patients with chronic hepatitis B","volume":"143","author":"Lok","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2020.05.003_bib9","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3748\/wjg.v16.i4.501","article-title":"Staging of liver fibrosis in chronic hepatitis B patients with a composite predictive model: a comparative study","volume":"16","author":"Wu","year":"2010","journal-title":"World J Gastroenterol: WJG."},{"key":"10.1016\/j.jceh.2020.05.003_bib10","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A\u00a0simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2020.05.003_bib11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4103\/ijmr.IJMR_1295_15","article-title":"Effect of vitamin D supplementation on sustained virological response in genotype 1\/4 chronic hepatitis C treatment-na\u00efve patients from India","volume":"148","author":"Behera","year":"2018","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.jceh.2020.05.003_bib12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","author":"European Association for the Study of the Liver","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2020.05.003_bib13","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2020.05.003_bib14","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1524-4733.2010.00777.x","article-title":"Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos (t)ides for treatment of nucleos(t)idenaive patients with chronic hepatitis B","volume":"13","author":"Dakin","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.jceh.2020.05.003_bib15","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/phar.1188","article-title":"Comparative efficacy of oral nucleoside or nucleotide analog monotherapy used in chronic hepatitis B: a mixedtreatment comparison meta-analysis","volume":"33","author":"Wiens","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jceh.2020.05.003_bib16","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1053\/j.gastro.2010.06.042","article-title":"Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and bayesian meta-analyses","volume":"139","author":"Woo","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2020.05.003_bib17","first-page":"2467","article-title":"Comparison of tenofovir and entecavir in patients with chronic HBV infection","volume":"17","author":"Ceylan","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jceh.2020.05.003_bib18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1155\/2016\/6725073","article-title":"Efficacy comparison of tenofovir and entecavir in HBeAg-positive chronic hepatitis B patients with high HBV DNA","volume":"2016","author":"Shi","year":"2016","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.jceh.2020.05.003_bib19","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4318\/tjg.2012.0380","article-title":"Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B","volume":"23","author":"Dogan","year":"2012","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.jceh.2020.05.003_bib20","first-page":"477","article-title":"Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis","volume":"59","author":"Guzelbulut","year":"2012","journal-title":"B.\u00a0Hepatogastroenterology"},{"key":"10.1016\/j.jceh.2020.05.003_bib21","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013983","article-title":"Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-na\u00efve HBeAg-positive patients with chronic hepatitis B. A large, multicentre, randomized controlled trials","volume":"98","author":"Cai","year":"2019","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jceh.2020.05.003_bib22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","article-title":"Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study","volume":"5","author":"Choi","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jceh.2020.05.003_bib23","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.3748\/wjg.v25.i33.4985","article-title":"Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations","volume":"25","author":"Choe","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2020.05.003_bib24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijid.2014.09.004","article-title":"Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naive patients with chronic hepatitis B: a multicenter real-life study","volume":"28","author":"Batirel","year":"2014","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jceh.2020.05.003_bib25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12876-017-0596-7","article-title":"Comparison of the long-term efficacy between entecavir and tenofovir in treatment- na\u00efve chronic hepatitis B patients","volume":"17","author":"Park","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jceh.2020.05.003_bib26","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1365-2036.2005.02453.x","article-title":"The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation","volume":"21","author":"van Zonneveld","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jceh.2020.05.003_bib27","first-page":"E 161","article-title":"Efficay and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: a randomized controlled trial","volume":"47","author":"Sriprayoon","year":"2016","journal-title":"Hepatol Res"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688320300657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688320300657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:06:51Z","timestamp":1760854011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688320300657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0973688320300657"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2020.05.003","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tenofovir is Superior to Entecavir in Patients with Treatment-na\u00efve Hepatitis B e-Antigen\u2013Positive Chronic Hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2020.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}